Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gal Markel

Showing results (1-10 of 137) with videos related to

Pageof 14
Sort By:
Accountability in Research|July 2, 2021
The common sense behind clinical trial names: An empirical study of trial acronymsTomer Meirson, Gal Markel, David Bomze
Current Pharmaceutical Design|February 1, 2014
MicroRNAs in cancer: lessons from melanomaEyal Greenberg, Yael Nemlich, Gal Markel
Bioinformatics (Oxford, England)|August 21, 2020
Structural basis of SARS-CoV-2 spike protein induced by ACE2Tomer Meirson, David Bomze, Gal Markel
Advanced Drug Delivery Reviews|July 6, 2019
Reprogramming lymphocytes for the treatment of melanoma: From biology to therapyNaama Margolis, Ettai Markovits, Gal Markel
Seminars in Cancer Biology|August 9, 2006
Tumor and viral recognition by natural killer cells receptorsTal I Arnon, Gal Markel, Ofer Mandelboim
BMC Gastroenterology|November 18, 2024
Survival outcomes of population-wide colonoscopy screening: reanalysis of the NordICC dataTomer Meirson, Gal Markel, Daniel A Goldstein
The Israel Medical Association Journal : IMAJ|February 28, 2008
Colchicine for the prevention of recurrent pericarditisGal Markel, Massimo Imazio, Antonio Brucato, et al.
Neurotoxicology|January 20, 2009
The possible use of oximes as antidotal therapy in organophosphate-induced brain damageShai Shrot, Gal Markel, Tsvika Dushnitsky, et al.
Bioinformatics (Oxford, England)|May 6, 2024
Peptriever: a Bi-Encoder approach for large-scale protein-peptide binding searchRoni Gurvich, Gal Markel, Ziaurrehman Tanoli, et al.
Cancers|June 26, 2020
Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event EvaluationTomer Meirson, Nethanel Asher, David Bomze, et al.
Pageof 14

Showing results (1-10 of 137) with videos related to

Sort By:
Pageof 14
Accountability in Research|July 2, 2021
The common sense behind clinical trial names: An empirical study of trial acronymsTomer Meirson, Gal Markel, David Bomze
Current Pharmaceutical Design|February 1, 2014
MicroRNAs in cancer: lessons from melanomaEyal Greenberg, Yael Nemlich, Gal Markel
Bioinformatics (Oxford, England)|August 21, 2020
Structural basis of SARS-CoV-2 spike protein induced by ACE2Tomer Meirson, David Bomze, Gal Markel
Advanced Drug Delivery Reviews|July 6, 2019
Reprogramming lymphocytes for the treatment of melanoma: From biology to therapyNaama Margolis, Ettai Markovits, Gal Markel
Seminars in Cancer Biology|August 9, 2006
Tumor and viral recognition by natural killer cells receptorsTal I Arnon, Gal Markel, Ofer Mandelboim
BMC Gastroenterology|November 18, 2024
Survival outcomes of population-wide colonoscopy screening: reanalysis of the NordICC dataTomer Meirson, Gal Markel, Daniel A Goldstein
The Israel Medical Association Journal : IMAJ|February 28, 2008
Colchicine for the prevention of recurrent pericarditisGal Markel, Massimo Imazio, Antonio Brucato, et al.
Neurotoxicology|January 20, 2009
The possible use of oximes as antidotal therapy in organophosphate-induced brain damageShai Shrot, Gal Markel, Tsvika Dushnitsky, et al.
Bioinformatics (Oxford, England)|May 6, 2024
Peptriever: a Bi-Encoder approach for large-scale protein-peptide binding searchRoni Gurvich, Gal Markel, Ziaurrehman Tanoli, et al.
Cancers|June 26, 2020
Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event EvaluationTomer Meirson, Nethanel Asher, David Bomze, et al.
Pageof 14